C omplement activation has been shown to occur in many pathological states, including renal, cardiovascular, neurological, allergic, and infectious disorders. The complement system is a collection of soluble and membrane-bound proteins that are grouped together. Three main pathways for complement activation have been recognized: the classical, alternative, and lectin pathways. Among these processes, C3 is central to the function of all 3 pathways and C3 convertase-induced production of cleavage products mediate numerous biological activities and then act on the C5 convertase. Enzymatic cleavage of C5 initiates the terminal complement cascade, leading to polymerization of C9 and insertion of membrane attack complex into cell membranes. The complement pathway activation acts in a cascade-like system to induce their physiological effects through specific receptors (such as C3aR [C3a receptor], C5aR [C5a receptor], and CR1), to facilitate migration of immune cells and promote inflammatory factor expression. [1] [2] [3] [4] [5] In addition to the known synthetic machinery in the extracellular milieu, activation of complement is also operative inside cells and may have multiple effects ranging from direct antimicrobial defense to cell differentiation and possible influence on metabolism. 6 Complement proteins also have multiple emerging novel functions in brain development, including progenitor proliferation, neuronal migration, and synaptic pruning. 7 We herein mainly review the role of complement proteins in hypertension and related vascular dysfunction and target organ damage.
Complement-Mediated Inflammation in Hypertension
Hypertension is recognized to be a state of chronic low-grade inflammation, with elevated levels of inflammatory cytokines and with activation of the immune system. In hypertension, innate and adaptive immune cells accumulate in the blood vessels, kidney and heart, where they communicate with the resident cells (eg, vascular smooth muscle cells [VSMCs] , endothelial cells [ECs] , and cardiofibroblasts) through the production of various factors, including reactive oxygen species, cytokines, and MMP (matrix metalloproteinases). 8, 9 In experimental models of Ang II (angiotensin II)-induced hypertension and in deoxycorticosterone acetate (DOCA)-salt hypertension, complement activation-mediated production of C3a and C5a induces C3aR and C5aR expression in the heart, kidney, and perivascular tissues. 10, 11 Although the initiation of complement cascade in hypertension is still unknown, significant progress in the past 2 decades provides evidence that these factors are involved in the regulation of hypertensionrelated innate and adaptive immune cell activation, and vascular dysfunction.
Complement and Innate Immunity in Hypertension
Different subpopulations of cells involved in innate and adaptive immune responses, such as dendritic cells and monocytes/ macrophages, on the one hand, and B and T lymphocytes, on the other, contribute to vascular dysfunction and target organ damage in hypertension. 8, 9 The role of monocytes/macrophages in hypertension is demonstrated using genetic mouse models. The mice with colony stimulating factor 1 mutationinduced monocyte/macrophage dysfunction or selective ablation of lysozyme M-positive monocytes are shown to prevent Ang II or DOCA salt-induced blood pressure (BP) elevation and vascular dysfunction. 12, 13 Our group previously showed that C3 is expressed in F4/80 positive macrophages in hypertensive mice, and macrophage depletion with clodronate liposomes blocks DOCA salt-induced increase of C3a and C5a production.
14 Although C3 or C3a does not affect macrophage infiltration and inflammatory factors expression in the Ang II or DOCA salt-induced hypertensive models, complement cascade downstream effector C5a promotes macrophage infiltration in the perivascular adipose tissue, induces proinflammatory M1 macrophage polarization and inflammatory factors expression, which in turn leads to reduction of the protective adipokine adiponectin in the perivascular adipose tissue. Macrophage depletion prevents the effects of C5a on perivascular adipose tissue-derived adiponectin expression and attenuates C5a-induced vascular remodeling in DOCAsalt hypertensive mice. 14, 15 Ang II infusion induces C5aR expression, and a majority of infiltrated C5aR-expressing cells are F4/80 positive macrophages, with a smaller fraction being Ly6G positive neutrophils. C5aR deficiency inhibits CD11b positive macrophage infiltration, decreases inflammatory factors expression, including IL (interleukin)-1β, MCP1 (monocyte chemoattractant protein 1), and MIP-1α (macrophage inflammatory protein 1α) in Ang II-infused mice. 11 Similarly, C5aR antagonist peptide attenuates immune cell infiltration and IL-1β, MCP1, and TNF-α (tumor necrosis factor α) production after Ang II infusion. 16 Sumida et al 17 reported that macrophages are recruited into the aortic adventitia soon after BP elevation and secrete complement C1q, which activates β-catenin signaling with C1r and C1s and induces proliferation of VSMCs, resulting in the progression of hypertension-induced pathological arterial remodeling in Ang II-infused mice.
Complement and Adaptive Immunity in Hypertension
T-cell function is also involved in the regulation of BP elevation and hypertensive cardiovascular disease. Mice lacking the recombination-activating gene 1, which lack both T and B cells, develop blunted hypertension and have preserved vascular endothelial function when infused with Ang II or after challenge with DOCA salt. 18 Further study showed that CD8+ and CD4+ T cells participate in BP elevation and target organ damage via producing IFN (interferon)-γ and IL-17. IFN-γ neutralizing antibodies or IL-17 deficiency prevents Ang II-induced BP elevation, as well as displays preserved vascular function, decreased superoxide production, and renal damage. [19] [20] [21] [22] [23] In contrast, regulatory T cells (Tregs), a subpopulation of CD4+ T cells with CD25 and Foxp3 positive, have been shown to modulate hypertension. Adoptive transfer of Tregs into wild-type (WT) mice reduced the hypertension, endothelial dysfunction, immune cell infiltration, and cardiorenal disorder caused by Ang II or aldosterone. [24] [25] [26] T-cell function is also affected by complement factors. C5a/ C5aR signaling exerts its regulatory activity on TLR4 (tolllike receptor 4) activation and cytokine production by macrophages, which subsequently promote the differentiation/ expansion of self-reactive T cells to Th17 cells. 27 In contrast, C3a/C3aR and C5a/C5aR downregulate the function of CD4+Foxp3+ circulating Tregs via directly modulating the AKT and Foxo1 pathways. 28, 29 However, absence of C3aR and C5aR signals in CD4+ T cells induces Foxp3+ Treg differentiation, and activation of CD4+ T cells from mice deficient in both C3aR and C5aR leads to a lower abundance of the proinflammatory cytokines IL-6 and IFN-γ but a greater abundance of the anti-inflammatory cytokines IL-10 and TGF-β1. 30 We recently showed that Ang II-induced hypertension results in an elevated expression of C3aR and C5aR in Foxp3+ Tregs. C3aR and C5aR double deficiency decrease both systolic and diastolic BP in response to Ang II compared with WT, single C3aR-deficient, or C5aR-deficient mice via activating Foxp3+ Tregs. Depletion of Tregs with CD25 neutralizing antibodies abolishes the protective effects against Ang II-induced hypertension and target organ damage in C3aR and C5aR double-deficient mice. Adoptive transfer of C3aR and C5aR double-deficient Tregs shows much more profound protective effects against Ang II-induced BP elevation and renal damage than WT Treg transfer. 31 Innate and adaptive immune cells are both involved in the process of hypertension-related complement activation. However, it is difficult to get a conclusion that complement activation is essential to cause hypertension or hypertension induces complement activation. Although several studies have demonstrated that complement-mediated immunoreaction and inflammation play a critical role in the development of hypertension. It may be a feedback between complement activation and hypertension. Hypertension induces complement activation, and complement proteins accelerate hypertension.
Complement-mediated Vascular Dysfunction in Hypertension
Complement-mediated changes of the blood vessels include an altered vascular structure and function, as well as an increase of vascular inflammation. Several studies have shown various changes of vascular cells in hypertension. Both nitric oxide (NO) production and eNOS (endothelial NO synthase) activity are reduced, whereas production of reactive oxygen species is increased in ECs in hypertension. There is also evidence indicating that hypertensionassociated functional changes occur in VSMCs, including phenotype transdifferentiation, increased proliferation and migration, and production of elastase and MMPs. Besides, activation of adventitial fibroblasts is involved in the regulation of hypertensive vascular injury and related vascular disorders. Recently, some research groups, including ours, have examined the role of complement activation on the pathogenesis of hypertension-associated vascular diseases such as atherosclerosis and aortic aneurysm in vivo and in vitro using genetic mouse models.
Complement in Endothelial Dysfunction
Complement active fragments and regulators first encounter the vascular endothelium in vasculature from capillaries to larger arteries and interact with complement receptors to regulate endothelial cell function. Complement C1q stimulates EC proliferation and migration and promotes tube formation and sprouting of new vessels in a rat aortic ring assay.
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C1INH (Complement regulatory protein C1 inhibitor) prevents EC injury via reducing VCAM (vascular cell adhesion molecule)-1 expression and blocking leukocyte adhesion to EC monolayer. 33, 34 C1INH is a naturally occurring, unique serine protease inhibitor of C1r and C1s, it also controls the mannose-binding lectin-associated proteases MASP-1 (mannan-binding lectin-associated serine protease) and MASP-2 within the lectin pathway. C1INH treatment attenuates the recruitment of neointimal and medial macrophage and CD3+ T cell, inhibits C3 and C3c deposition, and protects against neointima formation after arterial injury.
35 C3-deficient mice showed decreased expression of P-selectin, E-selectin, ICAM (intercellular cell adhesion molecule)-1), and VCAM-1 in the brain microvasculature after lipopolysaccharide administration. 36 C3a activated the phosphorylation of p38 MAPK (mitogen-activated protein kinase) and NF-κB (nuclear factor-κB) and induced the upregulation of VCAM-1 and ICAM-1 expression in murine primary cerebral ECs. 36 The downstream active fragment C5a induces ICAM-1 and PAI (plasminogen activator inhibitor)-1 expression in ECs in a C5aR-dependent manner, possibly accounting for neointima formation after arterial injury. 37, 38 However, complement inhibitory proteins, including DAF (decay accelerating factor), CD46, and CD59, which attenuate complement cascade activation and improve complement-mediated lysis, could be upregulated by CRP (C-reactive protein) and shear stress in ECs. 39 , 40 Emin et al 41 demonstrated that intermittent hypoxia-induced cholesterolenriched lipid raft formation in EC promotes internalization of CD59, thus decreases its protection against complement activity and increases deposition of the membrane attack complex in ECs, which contribute to endothelial inflammation and vascular injury in obstructive sleep apnea. Wu et al 42 reported that CD59-mediated inhibition of membrane attack complex formation attenuates endothelial damage and reduce foam cell formation in an atherosclerosis mouse model. Similarly, DAF deficient mice show increased leukocyte accumulation, cellular proliferation, and neointimal thickening after femoral artery wire injury versus WT mice. 43 In addition, accumulating evidence indicates that endothelial-to-mesenchymal transition contributes to the development of various cardiovascular diseases, including myocardial infarction and cardiac fibrosis. 44 We recently showed that Ang II-induced hypertension causes an increased reactive oxygen species and renal fibrosis, accompanied with induction of endothelial-to-mesenchymal transition in the kidney. 45 Curci et al 46 showed that C3a and C5a lead to altered endothelial phenotype with increased expression of fibroblast markers and decrease expression of specific endothelial markers via activating Akt signaling pathway. Li et al 47 further demonstrated that C3aR and C5aR antagonist peptides ameliorate endothelial-to-mesenchymal transition via the Wnt/β-catenin signaling pathway. These provide a potential possibility that complement activation-mediated endothelial-to-mesenchymal transition may contribute to hypertensive vascular dysfunction. Taken together, complement activation promotes inflammatory factor expression in ECs, performs a chemotaxis to recruit immune cells, results in decreased eNOS expression and NO production, and finally initiates vascular injury.
Complement in Vascular Remodeling
VSMCs are highly specialized cells contributing to the formation of blood vessel walls and maintenance of vascular tension. For vascular remodeling in hypertension, it is essential that VSMCs switch from a contractile to a synthetic phenotype to proliferate, migrate, and secrete factors. VSMCs from spontaneously hypertensive rats (SHR) show the synthetic phenotype and exaggerated growth in comparison with VSMCs from normotensive Wistar-Kyoto rats. 48 Lin et al 49 investigated the genes associated with the synthetic phenotype and exaggerated growth of VSMCs from SHR by microarray and found that preprocomplement 3 (prepro-C3) are expressed only in VSMCs from SHR, not Wistar-Kyoto. Exogenous C3 changes VSMCs to the synthetic phenotype. Antisense oligodeoxynucleotides to C3 reduce the higher level of DNA synthesis in VSMCs from SHR. Antisense oligodeoxynucleotides to C3 increases expression of SM22α mRNA and decreases expression of osteopontin, matrix Gla, and growth factor mRNAs in VSMCs from SHR. 49 This group further demonstrated that ERK (extracellular signal-regulated kinase) signaling pathway activation-mediated expression of KLF5 (Krüppel-like zinc-finger transcription factor 5) is critical for C3a-induced VSMC phenotypic changes. 50 Sumida et al 17 showed that alternatively activated macrophages are recruited to the aortic adventitia after Ang IIinduced BP elevation and secrete C1q. Macrophage-derived C1q and VSMC-derived C1r/s compose the C1 complex, which plays a pivotal role in initiating hypertensive arterial remodeling through activating β-catenin signaling in VSMCs and inducing VSMC proliferation. However, complement activation-induced membrane attack complex deposition in VSMCs promotes MCP1 release and is chemotactic for freshly isolated peripheral blood monocytes. 51 Verdeguer et al 52 demonstrated that C3 and C3a promote macrophage and VSMC proliferation through Gi protein-dependent activation of ERK1/2, which could be blocked by C3 neutralizing antibodies or C3aR antagonist peptides. These suggest that complement factors provide a link between recruited macrophages and VSMCs in hypertension, and complementmediated macrophage-VSMC interaction may be a novel therapeutic target to prevent vascular dysfunction in patients with hypertension.
As mentioned above, during the development of vascular diseases, endothelial dysfunction in the tunica intima is believed to be an initiator that is followed by infiltration of complement-activated inflammatory cells, and then VSMCs in the tunica media dedifferentiate, proliferate and migrate into the intima together with inflammatory cells to form the neointima. In this process, the tunica adventitia has been regarded as a supportive connective tissue and has thus been largely neglected. Interestingly, recent studies indicate that the tunica adventitia is the most complex layer of the blood vessel and contains fibroblasts, adipocytes, vascular progenitors, and immune cells. We and others have previously demonstrated that Ang II induces adventitial fibroblast migration and proliferation, reactive oxygen species production and collagen deposition and theses together contribute to vascular stiffening and aortic fibrosis in hypertension. [53] [54] [55] [56] [57] Our study showed that adventitial macrophage secretes C3 and C5, which promotes adventitial fibroblast migration and induces myofibroblast differentiation in DOCA-salt hypertensive model. C5aR antagonist treatment attenuates macrophage recruitment in the adventitia and improves hypertension-induced adventitial collagen deposition and vascular fibrosis. 14, 15, 58 Vascular dysfunction is the major pathological basis of hypertension-related cardiovascular disease. Its occurrence and development are closely associated with complement activation. Complement proteins could directly regulate vascular function through complement receptors expressed in EC, VSMC, and adventitial fibroblast. Besides, complementmediated immune cell activation and inflammation also induces vascular cell dysfunction. These studies emphasize the complexity of complement in regulating hypertensionrelated vascular dysfunction (Figure) .
Complement in Hypertensive Target Organ Damage
The target organs of hypertension are the heart, the brain, the vasculature, and the kidneys. The role of complement activation in the regulation of vasculature has been reviewed in the previous section, and little attention has been focused on the brain damage in hypertension. Here, we mainly focus on the role of complement in hypertension-induced cardiac and renal damage (Figure) . Shagdarsuren et al 10 reported that C1q, C3, C3c, and C5b-9 are observed in the heart and kidney in Ang II-induced model. C5b-9 colocalizes with IL-6. Losartan and aliskiren reduced albuminuria and complement expression. TNF-α and CRP played a major role in promoting C3 expression in renal tubular epithelial cells, TNF-α blockade markedly reduces C1q and C3 activation in the kidney. 10 In the Dahl Salt-Sensitive rat model, transcriptomic studies indicate that the complement pathway is upregulated in the kidney. However, recombinant sCR1 (a soluble form of endogenous complement receptor 1) treatment does not alter the development of hypertension, albuminuria, or renal damage in Dahl Salt-Sensitive hypertension model. 59 Zhou et al 60 showed that C3a induces an epithelial-to-mesenchymal transition in renal epithelial cells, which displays increased expression of renin and KLF5. C3 and renin are strongly stained in the degenerated nephrotubulus and colocalized with prorenin receptors in unilateral ureteral obstruction kidneys from WT mice. In C3-deficient mice, the epithelial-to-mesenchymal transition is suppressed, with no expression of renin and C3. After unilateral ureteral obstruction, systolic BP is increased in WT but not C3-deficient mice. In WT but not C3-deficient mice, intrarenal Ang II levels are markedly higher in unilateral ureteral obstruction kidneys than normal kidneys and decrease with aliskiren treatment. 60 These provide evidence that C3 may be a primary factor for activating the renal renin-angiotensin system to induce hypertension. Raij et al 61 demonstrated that WT mice have more severe glomerulosclerosis, proteinuria, C9 deposition, and renal insufficiency than C5 deficient mice in DOCA salt-induced hypertension. Weiss et al 62 further showed that C5aR is mainly expressed in the dendritic cells and macrophages in the kidney of Ang II-infused mice. C5aR deficiency attenuates Ang II-induced glomerular damage and albuminuria, as well as decreases inflammatory factor expression in the kidney. However, C5aR deficiency does not affect Ang II-induced BP elevation, and the infiltration of immune cell, including dendritic cells, macrophages, and T cells, shows no difference compared with WT mice. 62 We showed that C3aR and C5aR double-deficient mice have a decreased macrophage and T-cell infiltration, but an increased Treg recruitment in the kidney, which results in blunted BP elevation and decreased renal damage in Ang II-induced hypertension. 31 As discussed above, complement activation leads to generation of cleavage fragments like C3a and C5a in the heart of hypertension models. 11 The role of complement activation in hypertensive cardiac remodeling has recently been examined. Ang II induces a similar degree of hypertension and cardiac hypertrophy in WT, CD59-deficient, and C3-deficient mice. 63 C3aR-deficiency has no significant effects on BP elevation and cardiac remodeling in mice after Ang II infusion. 11 These observations argue against either a protective role for CD59 or participation of C3 in the pathogenesis of Ang II-induced renal damage and suggest a different pathological role of complement activation between cardiac remodeling and renal damage in hypertension. However, the critical roles of the C5a/C5aR axis in hypertensive cardiac remodeling have been clearly documented. Zhang et al 11 reported increased levels of C5a in humans with high BP. Hypertension caused by Ang II infusion leads to increased systemic C3a and C5a generation in mice. C5aR-deficient mice exhibit markedly reduced cardiac remodeling and inflammation after Ang II infusion. Pharmacological inhibition of C5a production by an anti-C5 monoclonal antibody or C5aR targeting with an inhibitor (PMX53) recapitulates the effects of C5aR deficiency. Bone marrow chimera experiments revealed that C5aR expression on bone marrow-derived cells is critical in mediating Ang II-induced cardiac remodeling. 11, 16 Treatment of DOCA-salt hypertensive rats with PMX53 attenuates inflammation and decreases hypertensive cardiac remodeling. PMX53 treatment results in less ventricular collagen deposition and hypertrophy as compared with untreated hypertensive rats. 64 It is worth noted that C3aR-deficient mice have a tendency towards greater cardiac injury and accelerate muscle injury in a macrophage-dependent manner. 11, 65 Besides, C5aR activation contributes to renal damage but protects the heart in Ang II-induced hypertension. 62 These suggest a paradoxical effect of complement activation in hypertension-induced target organ damage, and the mechanism needs much more investigation.
Potential Clinical Implications
Clinical studies on the role played by complement activation in the development of hypertension are limited. However, there are several clinical observations about the association of complement factors and hypertension (Table) . In a population-based cohort in Sweden, almost 40% of the men with normal BP develop hypertension over 15 years of follow-up. C3 in the plasma is a risk factor for hypertension and still persists after adjustment for other risk factors. C4 is associated with BP at baseline but shows no relationship with development of hypertension. 66 A cross-sectional study showed that elevated serum C3 concentration is independently and positively associated with the prevalence of prehypertension in an adult Chinese population. 67 Magen et al 68, 71 reported that resistant hypertension is associated with higher blood levels of C3, C3a, and C3b, and a negative correlation is observed between C3a and blood levels of endothelial progenitor cells. Gonzalez-Calero et al 70 showed that CD59 is significantly altered in hypertensive patients developing albuminuria on chronic renin-angiotensin system suppression. Additionally, CD59 is able to predict in normoalbuminuric individuals who will develop albuminuria in the future.
It is worth noted that complement gene abnormalities and increased complement activation predispose to the development of preeclampsia in women. Lokki et al 72 found that 3 single nucleotide polymorphisms within the C3 gene are associated with severe preeclampsia. We and others also showed that women with increased alternative complement pathway activation are more likely to develop preeclampsia. 73, 74 Burwick et al 69 showed that eculizumab (a targeted inhibitor of C5) treatment in preeclampsia results in marked improvement in clinical and laboratory parameters without apparent adverse effects. Another important clinical use for eculizumab is to treatment of thrombotic microangiopathy-induced acute kidney injury and serve hypertension. [75] [76] [77] However, clinical trials optimally designed to evaluate clinical efficacy are needed to further investigate the relationship between complement activation and the development of hypertension-related target organ damage. Studies in specific high-risk subpopulations (eg, chronic inflammation) may be required to explore the potential benefit of inhibiting complement activation in addition to drug treatments of established value. As an important mechanism elucidating the association between complement and hypertension has been explored, we propose that target complement-mediated inflammation response will likely be a novel therapeutic strategy in future hypertension medications.
Conclusions
In conclusion, BP elevation induces the activation of complement system and production of complement factors. These factors accelerate the progression of vascular injury and promote the development of hypertension via 2 different kinds of regulation. First, complement factors directly promote vascular cell dysfunction through their specific receptors in effector cells. However, complement activation mediates immune cell recruitment and induces inflammatory factor production in these cells. These together aggravate hypertension-induced target cardiorenal organ damage (Figure) . However, additional studies are needed to identify how the complement cascade pathway leads to vascular dysfunction, kidney injury, cardiac remodeling, and hypertension. Furthermore, downstream signaling mediators of complement factors need to be better studied. Finally, more studies are needed to harness the potential of complement system in the design of novel therapeutic approaches to hypertension, renal, and cardiovascular diseases. 
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